DBV Technologies peanut allergy drug fails key study [Reuters]
DBV Technologies S.A. - American Depositary Shares (DBVT)
US:NASDAQ Investor Relations:
dbv-technologies.com/en/investor-relations
Company Research
Source: Reuters
DBV Technologies peanut allergy drug fails key study | Reuters 2 Min Read Oct 20 (Reuters) - Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study. The trial, which tested a 250 microgram stick-on patch called Viaskin Peanut, in 356 children between the ages of 4-11, missed the main goal of achieving a certain tolerance to peanut protein. ( bit.ly/2xbQD5H ) Preliminary results show 12 months of the treatment resulted in 35.3 percent of patients achieving a certain tolerance, versus a higher-than-expected 13.6 percent response from a placebo group. However, DBV said the results showed a statistically significant response with a favorable tolerability profile. Plans to submit a marketing application for the patch to the U.S. Food and Drug Administration (FDA) next year remain unchanged, the French drug developer said. There are currently no U.S. regulator-approved treatments for peanut allergies
Show less
Read more
Impact Snapshot
Event Time:
DBVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DBVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DBVT alerts
High impacting DBV Technologies S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
DBVT
News
- DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Egg Allergy Drug Pipeline Research 2024 Featuring Aimmune Therapeutics, DBV Technologies, and ASIT Biotech [Yahoo! Finance]Yahoo! Finance
- DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Peanut Allergy Drug Landscape Analysis Report 2024: Comprehensive Insights of 12+ Companies and 15+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024GlobeNewswire
DBVT
Earnings
- 10/31/23 - Miss
DBVT
Analyst Actions
- 2/21/24 - HC Wainwright
DBVT
Sec Filings
- 4/8/24 - Form PRE
- 3/11/24 - Form 4
- 3/8/24 - Form 8-K
- DBVT's page on the SEC website